Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$3.97 USD
-0.06 (-1.49%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $4.00 +0.03 (0.76%) 6:18 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Karyopharm Therapeutics Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
KPTI 3.97 -0.06(-1.49%)
Will KPTI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPTI
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
Other News for KPTI
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 | KPTI Stock News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI ...
JPMorgan Chase & Co. Expands Stake in Karyopharm Therapeutics Inc.
KPTI Downgraded to Neutral by HC Wainwright & Co. | KPTI Stock News
KPTI Downgraded by Analyst Amid Financial Concerns | KPTI Stock News